Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

Chronic Lymphocytic Leukemia Clinical Trial

Official title:

Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02991638
• Other study ID #: HKUBTK01
• Status: Recruiting
• Phase: Phase 3
• First received: December 2, 2016
• Last updated: April 11, 2018
• Start date: November 1, 2016
• Est. completion date: June 2021

Study information

• Verified date: April 2018
• Source: The University of Hong Kong
• Contact: King Hei Lu, MMedSc
• Phone: 852-22554361
• Email: khlu[@]hku.hk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Efficacy and Safety of ibrutinib in patients with chronic lymphocytic leukemia and other indolent B-cell lymphomas who are chronic hepatitis B virus carriers or occult hepatitis B virus carriers

Description:

Ibrutinib is a selective oral Burton tyrosine kinase inhibitor. Through interfering with the downstream pathways of B-cell receptor signaling, it inhibits proliferation and induces apoptosis in many B-cell lymphoid malignancies. The clinical benefit of ibrutinib has been demonstrated in patients with relapsed/refractory chronic lymphocytic leukaemia, mantle cell lymphoma, small lymphocytic lymphoma, and other indolent B-cell non-Hodgkin lymphomas.

The pivotal trials of ibrutinib excluded HBsAg+ patients. Therefore, the effects of ibrutinib on HBsAg+ and anti-HBc+ patients remain entirely undefined. In view of the B-cell signaling inhibitory activity of ibrutinib, which might be more potent than rituximab in suppressing B-cells, HBV reactivation in patients exposed previously to HBV infection, including chronic HBV carriers and occult HBV carriers, could be a major clinical problem.

To enable ibrutinib to be prescribed in Asia and other regions of the world where HBV is endemic, evidence-based recommendations on prevention of HBV reactivation in at-risk populations, including chronic HBV carriers (HBsAg+), and occult HBV carriers (HBsAg- but anti-HBc+), are urgently needed.

The following treatment regimens will be adopted. Relapsed / refractory chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma): 420 mg daily.

Relapsed / refractory mantle cell lymphoma: 560 mg daily. Relapsed / refractory indolent B-cell non-Hodgkin lymphoma: 560 mg daily. Treatment is continued until disease progression.

A total of 62 patients will be recruited, including 16 HBsAg+ patients, and 46 occult HBV carriers

Sample size calculation of occult HBV carriers For occult HBV carriers, the sample size is calculated according to the following information, based on our previous observations (as detailed in reference 3). The HBV reactivation rate in HBsAg-, anti-HBc+, anti-HBs+ patients is hypothesized to be 34%, which may increase to 68% in HBsAg-, anti-HBc+, but anti-HBs- patients [3]. Assuming a power of 80% and an alpha-risk of 0.1, together with the ratio of anti-HBs+ : anti-HBs- patients to be 2:1, we expect to recruit 42 HBsAg-, anti-HBc+ patients. With a dropout rate of 10%, the total number of patients to be recruited in this group will be 46.

Sample size calculation of HBsAg+ patients For HBsAg+ patients, the sample size is calculated according to the following information, based on our previous observations (as detailed in reference 3). The ratio of occult carriers (HBsAg-, anti-HBc+) : HBsAg+ patients is about 3: 1.3 Hence, the total number of HBsAg+ to be recruited will be 14 (42 divided by 3). With a drop-out rate of 10%, the total number of patients to be recruited in this group will be 16.

Approximate breakdown of number of patients in each category to be recruited Based on our previous observations on the proportions of low-grade B-cell lymphoid malignancies,8 an approximate breakdown of number of patients is as follows: follicular lymphoma (N=32), chronic lymphocytic leukemia/small lymphocytic lymphoma (N=11), marginal zone B-cell lymphoma (N=11), mantle cell lymphoma (N=5), and Waldenstrom macroglobulinemia (N=5).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 62
• Est. completion date: June 2021
• Est. primary completion date: December 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Adult patients between age of 18 - 80 years

2. Patients with indolent B-cell lymphoproliferative neoplasms that have relapsed or are refractory after at least one standard line of therapy that contains rituximab

3. Pathologically proven B-cell lymphoproliferative neoplasms including chronic lymphocytic leukaemia/small lymphocytic lymphoma, mantle cell lymphoma, marginal-zone B-cell lymphoma, and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma).

4. Pathologically proven follicular lymphoma, with relapse or disease progression > 12 months after previous rituximab therapy.

5. Chronic HBV carriers (HBsAg+)

6. Occult HBV carriers (HBsAg-, anti-HBc+ and HBV DNA-)

7. Haematology values within the following limits:

1. Absolute neutrophil count (ANC)1000/mm3 independent of growth factor support

2. Platelets 100,000/mm3, or 50,000/mm3 if bone marrow is involved, and independent of transfusion support in either situation

8. Biochemical values within the following limits:

1. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2 x upper limit of normal (ULN)

2. Total bilirubin = 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin

3. Serum creatinine = 2 x ULN or estimated Glomerular Filtration Rate (Cockcroft Gault) = 40 mL/min/1.73m2

9. Competent to give an informed consent

Exclusion Criteria:

1. Concomitant chronic liver diseases not related to HBV

2. Known history of drug-induced liver injury, chronic active hepatitis C infection, alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, on-going extra-hepatic obstruction caused by cholelithiasis, cirrhosis of the liver and portal hypertension

3. Known history of drug induced pneumonitis

4. Known history of inflammatory bowel disease

5. Woman who are pregnant or breast-feeding

6. Patients who do not consent to the use of effective contraception during the study

7. Active infections.

8. Evidence of ongoing active HBV hepatitis (ALT and/or AST > 2x upper limit of normal, and detectable HBV DNA)

9. Patients known to have histological transformation of CLL to an aggressive lymphoma

10. Vaccinated with live, attenuated vaccines within 4 weeks of enrolment

Related Conditions & MeSH terms

• Chronic Hepatitis B
• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis B, Chronic
• Hepatitis, Chronic
• Indolent B-cell Lymphomas
• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Follicular
• Lymphoma, Mantle-Cell
• Lymphoma, Small Lymphocytic
• Mantle-Cell Lymphoma
• Waldenstrom Macroglobulinemia
• Waldenstrom's Macroglobulinaemia

Intervention

Drug:
• Ibrutinib
Relapsed / refractory chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma): 420 mg daily Relapsed / refractory mantle cell lymphoma: 560 mg daily Relapsed / refractory indolent B-cell non-Hodgkin lymphoma: 560 mg daily Treatment is continued until disease progression

Locations

Country	Name	City	State
Hong Kong	The University of Hong Kong	Hong Kong

Sponsors (2)

Lead Sponsor	Collaborator
The University of Hong Kong	Janssen, LP

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall response rate (ORR)	proportion of patients achieving CR or partial remission (PR)	2 years
Primary	Duration of remission		two year
Primary	Rates of HBV Reactivation while on Ibrutinib therapy		two year
Primary	Adverse events and severe adverse events	Incidence of AE and SAE by severity grading as assessed according to CTCAE v4.03	two year